n.a. (GEVA)

238.60
2.80 1.19
NASDAQ
Prev Close 235.80
Open 236.64
Day Low/High 236.43 / 239.20
52 Wk Low/High 60.19 / 239.20
Volume 2.15M
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

Investors are most excited about Bluebird Bio (BLUE) and Pacira Pharmaceuticals (PCRX), according to Wedbush Securities, which is holding its annual healthcare investment conference in New York.

Alexion Completes Acquisition Of Synageva

Alexion Completes Acquisition Of Synageva

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that it has successfully completed its previously announced acquisition of Synageva BioPharma Corp.

New Lifetime High Today: Synageva BioPharma (GEVA)

New Lifetime High Today: Synageva BioPharma (GEVA)

Trade-Ideas LLC identified Synageva BioPharma (GEVA) as a new lifetime high candidate

Where the Money Was Made the Last 5 Years

Only one fund category (of 20) has beaten the S&P 500 over half a decade.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation Of The Board Of Directors Of Synageva BioPharma Corp.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation Of The Board Of Directors Of Synageva BioPharma Corp.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Synageva BioPharma Corp.

4 Big Biotech Companies to Sell Now

4 Big Biotech Companies to Sell Now

Biotech stocks are one of the hottest investment areas these days, but not all biotech stocks are smart buys.

SYNAGEVA BIOPHARMA CORP. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Synageva BioPharma Corp. Over The Proposed Sale Of The Company To Alexion Pharmaceuticals, Inc.

SYNAGEVA BIOPHARMA CORP. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Synageva BioPharma Corp. Over The Proposed Sale Of The Company To Alexion Pharmaceuticals, Inc.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Synageva BioPharma, Inc.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synageva BioPharma Corp. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synageva BioPharma Corp. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Synageva...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Synageva BioPharma Corp. Of Commencement Of An Investigation In Connection With The Fairness Of The Sale Of The Company To Alexion Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Synageva BioPharma Corp. Of Commencement Of An Investigation In Connection With The Fairness Of The Sale Of The Company To Alexion Pharmaceuticals, Inc.

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Synageva BioPharma Corp.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synageva BioPharma Corp. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synageva BioPharma Corp. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Synageva...

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Synageva BioPharma Corp. Of Commencement Of An Investigation Regarding The Fairness Of The Sale Of The Company To Alexion Pharmaceuticals, Inc. -- GEVA

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Synageva BioPharma Corp. Of Commencement Of An Investigation Regarding The Fairness Of The Sale Of The Company To Alexion Pharmaceuticals, Inc. -- GEVA

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Synageva BioPharma Corp.

SYNAGEVA BIOPHARMA CORP. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Synageva BioPharma Corp. Over The Proposed Sale Of The Company To Alexion Pharmaceuticals, Inc.

SYNAGEVA BIOPHARMA CORP. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Synageva BioPharma Corp. Over The Proposed Sale Of The Company To Alexion Pharmaceuticals, Inc.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Synageva BioPharma, Inc.

SYNAGEVA BIOPHARMA CORP. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Alexion Pharmaceuticals, Inc.

SYNAGEVA BIOPHARMA CORP. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Alexion Pharmaceuticals, Inc.

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Synageva...

Trade-Ideas: Synageva BioPharma (GEVA) Is Today's Unusual Social Activity Stock

Trade-Ideas: Synageva BioPharma (GEVA) Is Today's Unusual Social Activity Stock

Trade-Ideas LLC identified Synageva BioPharma (GEVA) as an unusual social activity candidate

Jim Cramer -- Why Is Janet Yellen Suddenly a Stock Commentator?

Jim Cramer -- Why Is Janet Yellen Suddenly a Stock Commentator?

The Fed chief used some pretty frightening terms about stocks Wednesday, saying that valuations 'generally are quite high' and that there are 'potential dangers' with them.

Fear of a 'Soliris Killer' Might Have Driven Alexion to Overpay for Synageva

Fear of a 'Soliris Killer' Might Have Driven Alexion to Overpay for Synageva

Investors see Alexion's willingness to write a huge check for Synageva as a tacit acknowledgment that Soliris' long-term future might be more at risk than the company lets on.

Microsoft Lags Dow in Tech Selloff; Yellen Spooks Wall Street

Microsoft Lags Dow in Tech Selloff; Yellen Spooks Wall Street

Stocks pared losses, though remained in the red by close as markets weighed comments from Federal Reserve Chair Janet Yellen that equity valuations were possibly stretched.

Yellen Warning About Overvalued Stocks Spooks Wall Street

Yellen Warning About Overvalued Stocks Spooks Wall Street

Stocks slump in the final hour of trading as markets weigh comments from Federal Reserve Chair Janet Yellen that warned of potentially overstretched equity valuations.

Cablevision Eyes Consolidation, Biotech Seen Nearing Bubble

Cablevision Eyes Consolidation, Biotech Seen Nearing Bubble

The Fast Money trading panel discussed whether biotech is in a bubble about to burst and weighed in on comments made by Cablevision's CEO on consolidating the New York Market.

Stocks Slump on Comments From Fed's Yellen; Herbalife Soars

Stocks Slump on Comments From Fed's Yellen; Herbalife Soars

Stocks are trading close to session lows by mid-afternoon Wednesday

Synageva Biopharma (GEVA) Stock More Than Doubles to 52-Week High on Alexion Acquisition

Synageva Biopharma (GEVA) Stock More Than Doubles to 52-Week High on Alexion Acquisition

Shares of Synageva Biopharma (GEVA) more than doubled to a 52-week high of $215.74 on Wednesday after Alexion Pharmaceuticals ALXN agreed to acquire it for $8.4 billion.

How to Trade the Market's Most Active Stocks

How to Trade the Market's Most Active Stocks

Here's how to trade some of the most active stocks on the market right now.